IQVIA Holdings Inc. $IQV Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 122,260 shares of the medical research company’s stock after purchasing an additional 4,701 shares during the period. Federated Hermes Inc. owned approximately 0.07% of IQVIA worth $19,267,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in IQV. Artisan Partners Limited Partnership acquired a new position in IQVIA in the 2nd quarter valued at about $515,772,000. Norges Bank purchased a new position in shares of IQVIA in the 2nd quarter valued at approximately $270,160,000. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after purchasing an additional 798,534 shares during the period. Laurel Wealth Advisors LLC raised its stake in shares of IQVIA by 15,755.2% during the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after purchasing an additional 774,681 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 2.4%

IQV opened at $218.20 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The company has a market cap of $37.16 billion, a price-to-earnings ratio of 29.93, a PEG ratio of 2.51 and a beta of 1.37. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $234.29. The business’s fifty day moving average is $215.90 and its two-hundred day moving average is $188.23.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter last year, the business posted $2.84 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IQV. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research note on Wednesday, September 3rd. TD Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating and boosted their price target for the stock from $206.00 to $215.00 in a research note on Monday, November 3rd. Barclays raised their price objective on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Finally, Truist Financial reissued a “buy” rating and set a $265.00 target price (up from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $241.44.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.